While stents have virtually eliminated many of the complications of abrupt artery closure, another problem remained: restenosis, or re-blocking. Boston Scientific was one of the first companies to develop a solution to the restenosis problem with the introduction of drug-eluting stents. Sometimes referred to as a 'coated' or 'medicated' stent, a drug-eluting stent is a normal metal stent that has been chemically etched (roughening of the surface) and then coated with a drug that is known to interfere with the process of restenosis. Coated stents have proven to be so successful in reducing re-blocking that it is predicted the demand for these products will double the current world market for stents to $5 billion annually. Given this fact, it's easy to understand Boston Scientifics' need for additional stent manufacturing capacity.
A New Facility in Minnesota:
The Boston Scientific Cardiology Group, located in the Minneapolis suburb of Maple Grove, develops medical technologies for interventional cardiologists, interventional radiologists, and vascular surgeons. Weaver Lake 3 is a new 150,000 square foot building located on the Maple Grove campus, providing spance for up to 600 new employees. It is on of two locations where Boston Scientific Manufactures its TAXUS Express paclitaxel-eluting coronary stent system, and the new building will house primary research and development laboratories and clean-rooms. Construction began in the fall of 2004 and is expected to be completed by the fall of 2005. Led by Boston Scientific engineers, the project design/build team consisted of : Kraus Anderson Construction Co., Hagen, Christensen &McIlwain Architects, Michaud Cooley Erickson Engineers and Metropolitan Mechanical Contractors.